Evaluation of the clinical efficacy and safety of topical calcipotriol/dipotassium glycyrrhizinate agents in the treatment of patients with psoriasis and limited skin involvement

Introduction. Psoriasis remains a major challenge in modern dermatology due to its high prevalence and chronic relapsing nature. A key therapeutic priority is the search for effective and safe topical agents capable of both managing flare-ups and providing long-term disease control.
Aim. To evaluate the clinical efficacy and safety of Depsoriol® lotion and cream (containing calcipotriol and dipotassium glycyrrhizinate) in patients with plaque psoriasis.
Materials and мethods. An open-label, multicenter observational study was conducted involving 108 patients (61 males, 47 females) aged 6 to 74 years across 18 Russian cities. Efficacy was assessed based on PASI score dynamics and patient satisfaction (5-point scale) over 6–8 weeks of therapy. Organoleptic properties and ease of use were also evaluated.
Results. A statistically significant reduction in the PASI score by 77.4% was observed (from 10.6 ± 9.3 to 2.4 ± 2.6 points; p < 0.001). The most pronounced improvement occurred in infiltration (83.5% reduction) and scaling (85.3% reduction), with the median for these parameters reaching 0 [0; 2] by the final visit. Erythema regression reached 73.3% (from 2.66 to 0.71 points). The therapeutic effect is driven by the synergism of calcipotriol (regulation of keratinocyte differentiation) and dipotassium glycyrrhizinate (potent anti-inflammatory and anti-cytokine activity).
Conclusion. Overall, 98.1% of participants rated the treatment results as positive. High treatment adherence was attributed to rapid itch relief and favorable organoleptic properties (fast absorption, non-greasy texture). The absence of steroid-related side effects and the positive safety profile support the use of Depsoriol® for long-term management, including proactive therapy for relapse prevention.

1. Кубанов АА, Карамова АЭ, Притуло ОА, Аршинский МИ, Знаменская ЛФ, Чикин ВВ и др. Псориаз: клинические рекомендации. 2023. 78 с. Режим доступа: https://www.rodv.ru/upload/iblock/a84/q6gxj2hn1mip4m1vaaqg1vyvsy05u11y.pdf.

2. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301–1315. https://doi.org/10.1016/S0140-6736(20)32549-6.

3. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212. https://doi.org/10.1111/jdv.13854.

4. Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323(19):1945–1960. https://doi.org/10.1001/jama.2020.4006.

5. Torsekar R, Gautam MM. Topical Therapies in Psoriasis. Indian Dermatol Online J. 2017;8(4):235–245. https://doi.org/10.4103/2229-5178.209622.

6. Salgado-Boquete L, Carrascosa JM, Llamas-Velasco M, Ruiz-Villaverde R, de la Cueva P, Belinchón I. A New Classification of the Severity of Psoriasis: What’s Moderate Psoriasis? Life. 2021;11(7):627. https://doi.org/10.3390/life11070627.

7. Lee HJ, Kim M. Challenges and Future Trends in the Treatment of Psoriasis. Int J Mol Sci. 2023;24(17):13313. https://doi.org/10.3390/ijms241713313.

8. Torsekar R, Gautam MM. Topical Therapies in Psoriasis. Indian Dermatol Online J. 2017;8(4):235–245. https://doi.org/10.4103/2229-5178.209622.

9. Maul JT, Anzengruber F, Conrad C, Cozzio A, Häusermann P, Jalili A et al. Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway. Dermatology. 2021;237(2):166–178. https://doi.org/10.1159/000512930.

10. Svendsen MT, Jeyabalan J, Andersen KE, Andersen F, Johannessen H. Worldwide utilization of topical remedies in treatment of psoriasis: a systematic review. J Dermatolog Treat. 2017;28(5):374–383. https://doi.org/10.1080/09546634.2016.1254331.

11. Bikle DD. Vitamin D and the skin: Physiology and pathophysiology. Rev Endocr Metab Disord. 2012;13(1):3–19. https://doi.org/10.1007/s11154-011-9194-0.

12. Kongsbak M, Levring TB, Geisler C, von Essen MR. The vitamin d receptor and T cell function. Front Immunol. 2013;4:148. https://doi.org/10.3389/fimmu.2013.00148.

13. Dyring-Andersen B, Bonefeld CM, Bzorek M, Løvendorf MB, Lauritsen JP, Skov L, Geisler C. The Vitamin D Analogue Calcipotriol Reduces the Frequency of CD8+ IL-17+ T Cells in Psoriasis Lesions. Scand J Immunol. 2015;82(1):84–91. https://doi.org/10.1111/sji.12304.

14. Ikeda U, Wakita D, Ohkuri T, Chamoto K, Kitamura H, Iwakura Y, Nishimura T. et al. 1α,25-Dihydroxyvitamin D3 and all-trans retinoic acid synergistically inhibit the differentiation and expansion of Th17 cells. Immunol Lett. 2010;134(1):7–16. https://doi.org/10.1016/j.imlet.2010.07.002.

15. Lovato P, Norsgaard H, Tokura Y, Røpke MA. Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell-Th17 cell axis in psoriasis. J Dermatol Sci. 2016;81(3):153–164. https://doi.org/10.1016/j.jdermsci.2015.12.009.

16. Segaert S, Duvold LB. Calcipotriol cream: a review of its use in the management of psoriasis. J Dermatolog Treat. 2006;17(6):327–337. https://doi.org/10.1080/09546630600999219.

17. Megna M, Cinelli E, Camela E, Fabbrocini G. Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data. Expert Rev Clin Immunol. 2020;16(6):599–620. https://doi.org/10.1080/1744666X.2020.1776116.

18. Yan R, Jiang S, Wu Y, Gao XH, Chen HD. Topical calcipotriol/betamethasone dipropionate for psoriasis vulgaris: A systematic review. Indian J Dermatol Venereol Leprol. 2016;82(2):135–144. https://doi.org/10.4103/0378-6323.175919.

19. Kruglova LS, Turbovskaya SN. Calcipotriol: modern possibilities of longterm psoriasis control in the course of a year. Klinicheskaya Dermatologiya i Venerologiya. 2017;16(2):53–59. (In Russ.) https://doi.org/10.17116/klinderma201716253-59.

20. Ren J, Zhu Q, Wang S, Li X, Sun Z, Li N et al. Clinical efficacy and safety of using calcipotriol-betamethasone compounding agent for psoriasis treatment: a systematic review and meta-analysis. Arch Dermatol Res. 2022;314(7):633–641. https://doi.org/10.1007/s00403-021-02272-5.

21. Qiong H, Han L, Zhang N, Chen H, Yan K, Zhang Z et al. Glycyrrhizin improves the pathogenesis of psoriasis partially through IL-17A and the SIRT1-STAT3 axis. BMC Immunol. 2021;22(1):34. https://doi.org/10.1186/s12865-021-00421-z.

22. Gao J, Guo J, Nong Y, Mo W, Fang H, Mi J et al. 18β-Glycyrrhetinic acid induces human HaCaT keratinocytes apoptosis through ROS-mediated PI3K-Akt signaling pathway and ameliorates IMQ-induced psoriasis-like skin lesions in mice. BMC Pharmacol Toxicol. 2020;21(1):41. https://doi.org/10.1186/s40360-020-00419-0.

23. Zhang Y, Wang Q, Sun S, Jiang L. The therapeutic effect of glycyrrhizic acid compound ointment on imiquimod-induced psoriasis-like disease in mice. PLoS ONE. 2023;18(8):e0290637. https://doi.org/10.1371/journal.pone.0290637.

24. Chen K, Yang R, Shen FQ, Zhu HL. Advances in Pharmacological Activities and Mechanisms of Glycyrrhizic Acid. Curr Med Chem. 2020;27(36):6219–6243. https://doi.org/10.2174/0929867325666191011115407.

25. Leite CDS, Bonafé GA, Pires OC, Santos TWD, Pereira GP, Pereira JA et al. Dipotassium Glycyrrhizininate Improves Skin Wound Healing by Modulating Inflammatory Process. Int J Mol Sci. 2023;24(4):3839. https://doi.org/10.3390/ijms24043839.

26. El-Saber Batiha G, Magdy Beshbishy A, El-Mleeh A, Abdel-Daim MM, Prasad Devkota H. Traditional Uses, Bioactive Chemical Constituents, and Pharmacological and Toxicological Activities of Glycyrrhiza glabra L. (Fabaceae). Biomolecules. 2020;10(3):352. https://doi.org/10.3390/biom10030352.

27. Gonçalves S, Fernandes L, Caramelo A, Martins M, Rodrigues T, Matos RS. Soothing the Itch: The Role of Medicinal Plants in Alleviating Pruritus in Palliative Care. Plants. 2024;13(24):3515. https://doi.org/10.3390/plants13243515.

28. Bisht D, Rashid M, Arya RKK, Kumar D, Chaudhary SK, Rana VS, Sethiya NK. Revisiting liquorice (Glycyrrhiza glabra L.) as anti-inflammatory, antivirals and immunomodulators: Potential pharmacological applications with mechanistic insight. Phytomed Plus. 2022;2(1):100206. https://doi.org/10.1016/j.phyplu.2021.100206.

29. Furuhashi I, Iwata S, Shibata S, Sato T, Inoue H. Inhibition by licochalcone A, a novel flavonoid isolated from liquorice root, of IL-1beta-induced PGE2 production in human skin fibroblasts. J Pharm Pharmacol. 2005;57(12):1661–1666. https://doi.org/10.1211/jpp.57.12.0017.

30. Imanishi N, Kawai H, Hayashi Y, Yatsunami K, Ichikawa A. Effects of glycyrrhizin and glycyrrhetinic acid on dexamethasone-induced changes in histamine synthesis of mouse mastocytoma P-815 cells and in histamine release from rat peritoneal mast cells. Biochem Pharmacol. 1989;38(15):2521–2526. https://doi.org/10.1016/0006-2952(89)90097-x.

31. Xu W, Li Y, Ju M, Lai W, Lu X, Shi H et al. A Multicenter, Randomized, DoubleBlind, Placebo-Controlled Study of Compound Glycyrrhizin Capsules Combined with a Topical Corticosteroid in Adults with Chronic Eczema. Evid Based Complement Alternat Med. 2020;2020:6127327. https://doi.org/10.1155/2020/6127327.

32. Hoffmann J, Gendrisch F, Schempp CM, Wölfle U. New Herbal Biomedicines for the Topical Treatment of Dermatological Disorders. Biomedicines. 2020;8(2):27. https://doi.org/10.3390/biomedicines8020027.

33. Lis-Święty A, Frątczak A. Proactive therapy: New perspectives for long-term topical treatment of psoriasis. Dermatol Ther. 2022;35(5):e15364. https://doi.org/10.1111/dth.15364.